Table S1. The specifications and codes for the indicator variables. Table S2. The validity results of the algorithms in the testing set (40% of the entire cohort). Figure S1. the algorithm with balanced sensitivity and positive predictive value for identifying recurrence of breast cancer. “Yes” means the criteria was met; “No” means the criteria was not met. Figure S2. the algorithm with balanced specificity and negative predictive value for identifying recurrence of breast cancer. “Yes” means the criteria was met; “No” means the criteria was not met. (DOCX 710 kb
Figure S1. Kaplan-Meier survival analysis stratified by histology (IDC vs. SCC) and nodal status in ...
Table S1. Hazard ratio (HR) and 95% confidence intervals (95% CIs) for discontinuation of adjuvant h...
Patient characteristics of the 6,248 patients shown by trial. Table S2. National Cancer Institute Co...
Figure S1. Cross table for calculation of sensitivity, specificity, PPV, NPV and accuracy. Figure S2...
Supplementary Figures and Tables. This file contains the following figures and tables: Validation of...
Table S1. Number of person-years, in situ and invasive breast cancer cases by detection mode, interv...
Table S2. Effects of BRCA germline mutation and other prognostic factors (all covariates) on clinica...
Is Table S1 presenting a description of study populations, Table S2 presenting KI67 immunohistochemi...
Figure S1. Kaplan-Meier estimates of disease-free survival (A), freedom from breast cancer recurrenc...
Table S3. Incidence of individual 21-gene Recurrence Scores from 11 to 25, and the comparative utili...
Figure S1. No difference in overall survival by use of chemotherapy for patients diagnosed betwee...
Table S3. Number of patients in each cell, by algorithm, The breakdown of the number of true positiv...
Table S3. Number of screen-detected cases, expected number of detected non-progressive in situ combi...
Table S1. Chemotherapy receipt by age group, with age separated into three tiers using 35 and 50 yea...
Table S2. Maximum-likelihood estimates (MLEs) and 95% confidence intervals (CIs) based on the non-ho...
Figure S1. Kaplan-Meier survival analysis stratified by histology (IDC vs. SCC) and nodal status in ...
Table S1. Hazard ratio (HR) and 95% confidence intervals (95% CIs) for discontinuation of adjuvant h...
Patient characteristics of the 6,248 patients shown by trial. Table S2. National Cancer Institute Co...
Figure S1. Cross table for calculation of sensitivity, specificity, PPV, NPV and accuracy. Figure S2...
Supplementary Figures and Tables. This file contains the following figures and tables: Validation of...
Table S1. Number of person-years, in situ and invasive breast cancer cases by detection mode, interv...
Table S2. Effects of BRCA germline mutation and other prognostic factors (all covariates) on clinica...
Is Table S1 presenting a description of study populations, Table S2 presenting KI67 immunohistochemi...
Figure S1. Kaplan-Meier estimates of disease-free survival (A), freedom from breast cancer recurrenc...
Table S3. Incidence of individual 21-gene Recurrence Scores from 11 to 25, and the comparative utili...
Figure S1. No difference in overall survival by use of chemotherapy for patients diagnosed betwee...
Table S3. Number of patients in each cell, by algorithm, The breakdown of the number of true positiv...
Table S3. Number of screen-detected cases, expected number of detected non-progressive in situ combi...
Table S1. Chemotherapy receipt by age group, with age separated into three tiers using 35 and 50 yea...
Table S2. Maximum-likelihood estimates (MLEs) and 95% confidence intervals (CIs) based on the non-ho...
Figure S1. Kaplan-Meier survival analysis stratified by histology (IDC vs. SCC) and nodal status in ...
Table S1. Hazard ratio (HR) and 95% confidence intervals (95% CIs) for discontinuation of adjuvant h...
Patient characteristics of the 6,248 patients shown by trial. Table S2. National Cancer Institute Co...